BTIG lowered the firm’s price target on Nurix Therapeutics (NRIX) to $27 from $35 and keeps a Buy rating on the shares. The firm cites the company having detailed their pivotal plans for bexobrutideg in r/r CLL – Relapsed or Refractory Chronic Lymphocytic Leukemia – and announced a concurrent raise of $250M, noting that the raise clears a financing overhang for the stock and providing a line of sight to key data catalysts and accelerating bexdeg’s I&I expansion, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics price target lowered to $21 from $22 at Wells Fargo
- Nurix Therapeutics Announces $250M Stock Offering
- Nurix Therapeutics price target raised to $29 from $28 at RBC Capital
- Nurix Therapeutics Initiates DAYBreak Phase 2 Trial
- Nurix prices 24.5M shares at $10.21 in underwritten registered offering